On April 29, 2020 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical data on its BTK inhibitor BRUKINSA (zanubrutinib) and its anti-PD-1 antibody tislelizumab will be presented in an oral presentation and three posters at the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place on May 29-31, 2020 (Press release, BeiGene, APR 29, 2020, View Source [SID1234556852]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation:

Title:

ASPEN: Results of a Phase III Randomized Trial of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM)

Abstract #: 8007

Session Title:
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Lead Author:

Constantine S. Tam, MBBS, M.D., St. Vincent’s Hospital, Australia

Poster Presentations:

Title:
Three-Year Follow-up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single-Agent Zanubrutinib

Abstract #: 8051

Poster #: 384

Session Title:
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Lead Author:
Constantine S. Tam, MBBS, M.D., St. Vincent’s Hospital, Australia

Title:

Phase 3 Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First line (1L) Treatment for Advanced Squamous Non-Small Cell Lung Cancer (sq NSCLC)

Abstract #: 9554

Poster #: 320

Session Title:

Lung Cancer—Non-Small Cell Metastatic Poster Session

Lead Author:

Jie Wang, M.D., Cancer Hospital Chinese Academy of Medical Sciences, China

Title:

Association Between Immune and Tumor Gene Signatures with Response or Resistance to Tislelizumab Monotherapy or in Combination with Chemotherapy in Gastroesophageal Adenocarcinoma

Abstract #: 3115

Poster #: 179

Session Title:

Developmental Therapeutics—Immunotherapy Poster Session

Lead Author
Jianming Xu, M.D., General Hospital of Chinese People’s Liberation Army, China